The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some ...

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.

Gray market grows for cheap weight-loss drugs imported from China, while some users try small doses of substances not yet ...

Wall Street Zen downgraded Eli Lilly from a "buy" to a "hold" rating, signaling caution amid a flurry of mixed analyst views. Despite this, Eli Lilly still holds strong support from other firms like ...

This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly) By Adam Spatacco – Updated Jun 30, 2025 at 7:04AM ...

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight management.

India approves Eli Lilly’s Mounjaro KwikPen, a once-weekly injection for type 2 diabetes and obesity, offering dual hormone action for improved blood sugar control and significant weight loss.